TG Therapeutics, Inc. (TGTX)Healthcare | Biotechnology | Morrisville, United States | NasdaqCM
54.34 USD
-0.93
(-1.683%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
After hours: 54.34 |
Hot Take ↕ | Oct. 10, 2026, 5:58 a.m. EDT
The long-term outlook remains fundamentally sound despite the recent price weakness. The company boasts exceptional profitability with a 55% profit margin and a staggering 100% return on equity, driven by a blockbuster drug that exceeded expectations. Revenue growth is robust at 70%, and the balance sheet is healthy with ample cash relative to debt. However, the market is currently punishing the stock, trading it at a discount despite these stellar metrics, likely due to fears of future clinical setbacks or regulatory hurdles. The recent price action shows a struggle to break above the 55-59 range, with the stock hovering near its 52-week high but failing to sustain momentum. While the business quality is top-tier, the lack of a confirmed catalyst to unlock the full valuation premium keeps the short-term outlook neutral. Investors should view the current dip as a potential entry point for a long-term hold, but patience is required until the next major data point resolves the lingering uncertainty. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.047240 |
| AutoETS | 0.047330 |
| MSTL | 0.048870 |
| AutoTheta | 0.158628 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 45% |
| H-stat | 0.12 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.113 |
| Excess Kurtosis | -0.74 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 124.89 |
| Revenue per Share | 5.61 |
| Market Cap | 8,317,772,288 |
| Trailing P/E | 19.76 |
| Forward P/E | 20.07 |
| Beta | 1.80 |
| Profit Margins | 55.22% |
| Website | https://www.tgtherapeutics.com |
As of Oct. 10, 2026, 5:58 a.m. EDT: Speculators are positioning for significant volatility rather than a clear directional bias. Call open interest is heavily concentrated at strikes 70 and 75, suggesting a speculative bet on a massive biotech catalyst or trial readout pushing the price toward $75+. Conversely, put open interest is stacked at deep strikes (20, 30, 40), indicating a hedge against a catastrophic failure or a 'buy the dip' strategy at lower valuations. The imbalance in volume versus open interest at deep strikes suggests active hedging by existing holders rather than fresh speculative entry. Implied volatility is elevated across the board, reflecting uncertainty around upcoming clinical data.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.6189221 |
| Address1 | 3,020 Carrington Mill Blvd. |
| Address2 | Suite 475 |
| All Time High | 233.4375 |
| All Time Low | 0.95625 |
| Ask | 61.34 |
| Ask Size | 1 |
| Audit Risk | 9 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 1,686,360 |
| Average Daily Volume3 Month | 2,001,648 |
| Average Volume | 2,001,648 |
| Average Volume10Days | 1,686,360 |
| Beta | 1.799 |
| Bid | 54.35 |
| Bid Size | 1 |
| Board Risk | 10 |
| Book Value | 4.258 |
| City | Morrisville |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 54.34 |
| Current Ratio | 4.267 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 55.3181 |
| Day Low | 53.63 |
| Debt To Equity | 124.89 |
| Display Name | TG Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,760,200 |
| Earnings Call Timestamp Start | 1,785,760,200 |
| Earnings Growth | -0.706 |
| Earnings Quarterly Growth | -0.724 |
| Earnings Timestamp | 1,785,760,200 |
| Earnings Timestamp End | 1,793,622,600 |
| Earnings Timestamp Start | 1,793,622,600 |
| Ebitda | 136,451,008 |
| Ebitda Margins | 0.17066 |
| Enterprise To Ebitda | 58.938 |
| Enterprise To Revenue | 10.059 |
| Enterprise Value | 8,042,139,136 |
| Eps Current Year | 0.95 |
| Eps Forward | 2.708 |
| Eps Trailing Twelve Months | 2.75 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 212 554 4531 |
| Fifty Day Average | 53.6542 |
| Fifty Day Average Change | 0.68579865 |
| Fifty Day Average Change Percent | 0.012781826 |
| Fifty Two Week Change Percent | 61.892212 |
| Fifty Two Week High | 59.3 |
| Fifty Two Week High Change | -4.959999 |
| Fifty Two Week High Change Percent | -0.08364248 |
| Fifty Two Week Low | 26.76 |
| Fifty Two Week Low Change | 27.58 |
| Fifty Two Week Low Change Percent | 1.0306427 |
| Fifty Two Week Range | 26.76 - 59.3 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,272,893,400,000 |
| Float Shares | 135,242,262 |
| Forward Eps | 2.708 |
| Forward P E | 20.066471 |
| Free Cashflow | 59,134,500 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 399 |
| Fullday Change | -0.9300003 |
| Fullday Change Percent | -1.6826494 |
| Fullday Price | 54.34 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.82372004 |
| Gross Profits | 658,596,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.07469 |
| Held Percent Institutions | 0.747 |
| Implied Shares Outstanding | 153,069,053 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,335,744,000 |
| Last Split Factor | 100:5625 |
| Long Business Summary | TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina. |
| Long Name | TG Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 8,317,772,288 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_143627354 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 441,489,984 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 8,547,375,919 |
| Number Of Analyst Opinions | 7 |
| Open | 55.23 |
| Operating Cashflow | 17,876,000 |
| Operating Margins | 0.090179995 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Peg Ratio | 1.61 |
| Phone | 212 554 4484 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 54.34 |
| Post Market Time | 1,791,922,800 |
| Previous Close | 55.27 |
| Price Eps Current Year | 57.2 |
| Price Hint | 2 |
| Price To Book | 12.761861 |
| Price To Sales Trailing12 Months | 10.403249 |
| Profit Margins | 0.55218 |
| Quick Ratio | 3.552 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.5 |
| Region | US |
| Regular Market Change | -0.9300003 |
| Regular Market Change Percent | -1.6826494 |
| Regular Market Day High | 55.3181 |
| Regular Market Day Low | 53.63 |
| Regular Market Day Range | 53.63 - 55.3181 |
| Regular Market Open | 55.23 |
| Regular Market Previous Close | 55.27 |
| Regular Market Price | 54.34 |
| Regular Market Time | 1,791,921,601 |
| Regular Market Volume | 998,213 |
| Return On Assets | 0.07276 |
| Return On Equity | 1.0028 |
| Revenue Growth | 0.703 |
| Revenue Per Share | 5.61 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 153,069,053 |
| Shares Percent Shares Out | 0.2001 |
| Shares Short | 30,634,421 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 30,128,901 |
| Short Name | TG Therapeutics, Inc. |
| Short Percent Of Float | 0.2893 |
| Short Ratio | 16.5 |
| Source Interval | 15 |
| State | NC |
| Symbol | TGTX |
| Target High Price | 86.0 |
| Target Low Price | 21.0 |
| Target Mean Price | 69.71429 |
| Target Median Price | 75.0 |
| Total Cash | 552,248,000 |
| Total Cash Per Share | 3.893 |
| Total Debt | 754,441,024 |
| Total Revenue | 799,536,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 2.75 |
| Trailing P E | 19.76 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 42.0077 |
| Two Hundred Day Average Change | 12.332298 |
| Two Hundred Day Average Change Percent | 0.2935723 |
| Type Disp | Equity |
| Volume | 998,213 |
| Website | https://www.tgtherapeutics.com |
| Zip | 27,560 |